Cytokine-Induced killer cells as pharmacological tools for cancer immunotherapy

Frontiers in Immunology

Volumn 8, Issue JUL, 2017, Pages

  Gao, Xingchun ^a,b,c   Mi, Yajing ^a,b   Guo, Na ^a   Xu, Hao ^a   Xu, Lixian ^b   Gou, Xingchun ^a   Jin, Weilin ^a,c,d  

^a XI'AN MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c Shanghai Jiao Tong University   (China)

^d SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Cancer therapy; Clinical trials; Cytokine induced killer cells; Immunotherapy; Pharmacological tools

Indexed keywords

ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; BRENTUXIMAB VEDOTIN; CD3 ANTIBODY; CHIMERIC ANTIGEN RECEPTOR; CISPLATIN; CYTOKINE; DENDRITIC CELL VACCINE; DOCETAXEL; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 7; NANOPARTICLE; OBINUTUZUMAB; RITUXIMAB; TEMOZOLOMIDE; TUMOR NECROSIS FACTOR;

ALLOIMMUNITY; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CELL EXPANSION; CYTOKINE INDUCED KILLER CELL; CYTOTOXICITY; DENDRITIC CELL; EX VIVO STUDY; GENETIC ENGINEERING; GLIOBLASTOMA; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE RESPONSE; MALIGNANT NEOPLASM; META ANALYSIS (TOPIC); NANOMEDICINE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); REVIEW; TH1 CELL; TUMOR ASSOCIATED LEUKOCYTE; VACCINATION;

EID: 85022182380     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2017.00774     Document Type: Review

References (147)

1. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncol (2012) 13(8):790-801. doi:10.1016/S1470-2045(12)70211-5
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 127(12):2893-917. doi:10.1002/ijc.25516
3. Yron I, Wood TA Jr, Spiess PJ, Rosenberg SA. In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors. J Immunol (1980) 125(1):238-45.
4. Lotze MT, Line BR, Mathisen DJ, Rosenberg SA. The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): implications for the adoptive immunotherapy of tumors. J Immunol (1980) 125(4):1487-93.
5. Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med (1991) 174(1):139-49. doi:10.1084/jem.174.1.139
6. Schmidt-Wolf IG, Lefterova P, Mehta BA, Fernandez LP, Huhn D, Blume KG, et al. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol (1993) 21(13):1673-9.
7. Kaneko T, Fusauch Y, Kakui Y, Okumura K, Mizoguchi H, Oshimi K. Cytotoxicity of cytokine-induced killer cells coated with bispecific antibody against acute myeloid leukemia cells. Leuk Lymphoma (1994) 14(3-4):219-29. doi:10.3109/10428199409049672
8. Zoll B, Lefterova P, Csipai M, Finke S, Trojaneck B, Ebert O, et al. Generation of cytokine-induced killer cells using exogenous interleukin-2, -7 or -12. Cancer Immunol Immunother (1998) 47(4):221-6. doi:10.1007/s002620050524
9. Schmidt-Wolf IG, Finke S, Trojaneck B, Denkena A, Lefterova P, Schwella N, et al. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer (1999) 81(6):1009-16. doi:10.1038/sj.bjc.6690800
10. Marten A, Ziske C, Schottker B, Renoth S, Weineck S, Buttgereit P, et al. Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations. J Immunother (2001) 24(6):502-10. doi:10.1097/00002371-200111000-00007
11. Verneris MR, Karimi M, Baker J, Jayaswal A, Negrin RS. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood (2004) 103(8):3065-72. doi:10.1182/blood-2003-06-2125
12. Jiang J, Xu N, Wu C, Deng H, Lu M, Li M, et al. Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells. Anticancer Res (2006) 26(3B):2237-42.
13. Contag CH, Sikorski R, Negrin RS, Schmidt T, Fan AC, Bachireddy P, et al. Definition of an enhanced immune cell therapy in mice that can target stem-like lymphoma cells. Cancer Res (2010) 70(23):9837-45. doi:10.1158/0008-5472.CAN-10-2650
14. Hontscha C, Borck Y, Zhou H, Messmer D, Schmidt-Wolf IG. Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol (2011) 137(2):305-10. doi:10.1007/s00432-010-0887-7
15. Schlimper C, Hombach AA, Abken H, Schmidt-Wolf IG. Improved activation toward primary colorectal cancer cells by antigen-specific targeting autologous cytokine-induced killer cells. Clin Dev Immunol (2012) 2012:238924. doi:10.1155/2012/238924
16. Dai C, Lin F, Geng R, Ge X, Tang W, Chang J, et al. Implication of combined PD-L1/PD-1 blockade with cytokine-induced killer cells as a synergistic immunotherapy for gastrointestinal cancer. Oncotarget (2016) 7(9):10332-44. doi:10.18632/oncotarget.7243
17. Lee HK, Kim YG, Kim JS, Park EJ, Kim B, Park KH, et al. Cytokine-induced killer cells interact with tumor lysate-pulsed dendritic cells via CCR5 signaling. Cancer Lett (2016) 378(2):142-9. doi:10.1016/j.canlet.2016.05.020
18. Linn YC, Lau LC, Hui KM. Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts. Br J Haematol (2002) 116(1):78-86. doi:10.1046/j.1365-2141.2002.03247.x
19. Schmidt TL, Negrin RS, Contag CH. A killer choice for cancer immunotherapy. Immunol Res (2014) 58(2-3):300-6. doi:10.1007/s12026-014-8507-2
20. Pievani A, Belussi C, Klein C, Rambaldi A, Golay J, Introna M. Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell (CIK) cultures and anti-CD20 antibodies. Blood (2011) 117(2):510-8. doi:10.1182/blood-2010-06-290858
21. Linn YC, Wang SM, Hui KM. Comparative gene expression profiling of cytokine-induced killer cells in response to acute myloid leukemic and acute lymphoblastic leukemic stimulators using oligonucleotide arrays. Exp Hematol (2005) 33(6):671-81. doi:10.1016/j.exphem.2005.03.005
22. Sangiolo D. Cytokine induced killer cells as promising immunotherapy for solid tumors. J Cancer (2011) 2:363-8. doi:10.7150/jca.2.363
23. Lu PH, Negrin RS. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol (1994) 153(4):1687-96.
24. Introna M, Franceschetti M, Ciocca A, Borleri G, Conti E, Golay J, et al. Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: an innovative proposal for the treatment of leukemia relapse after cord blood transplantation. Bone Marrow Transplant (2006) 38(9):621-7. doi:10.1038/sj.bmt.1705503
25. Todorovic M, Mesiano G, Gammaitoni L, Leuci V, Giraudo Diego L, Cammarata C, et al. Ex vivo allogeneic stimulation significantly improves expansion of cytokine-induced killer cells without increasing their alloreactivity across HLA barriers. J Immunother (2012) 35(7):579-86. doi:10.1097/CJI.0b013e31826b1fd9
26. Hayes MP, Wang J, Norcross MA. Regulation of interleukin-12 expression in human monocytes: selective priming by interferon-gamma of lipopolysaccharide-inducible p35 and p40 genes. Blood (1995) 86(2):646-50.
27. Ma X, Chow JM, Gri G, Carra G, Gerosa F, Wolf SF, et al. The interleukin 12 p40 gene promoter is primed by interferon gamma in monocytic cells. J Exp Med (1996) 183(1):147-57. doi:10.1084/jem.183.1.147
28. Lopez RD, Waller EK, Lu PH, Negrin RS. CD58/LFA-3 and IL-12 provided by activated monocytes are critical in the in vitro expansion of CD56+ T cells. Cancer Immunol Immunother (2001) 49(12):629-40. doi:10.1007/s002620000148
29. Ochoa AC, Gromo G, Alter BJ, Sondel PM, Bach FH. Long-term growth of lymphokine-activated killer (LAK) cells: role of anti-CD3, beta-IL 1, interferon-gamma and -beta. J Immunol (1987) 138(8):2728-33.
30. Anderson PM, Bach FH, Ochoa AC. Augmentation of cell number and LAK activity in peripheral blood mononuclear cells activated with anti-CD3 and interleukin-2. Preliminary results in children with acute lymphocytic leukemia and neuroblastoma. Cancer Immunol Immunother (1988) 27(1):82-8. doi:10.1007/BF00205763
31. Leemhuis T, Wells S, Scheffold C, Edinger M, Negrin RS. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant (2005) 11(3):181-7. doi:10.1016/j.bbmt.2004.11.019
32. Baker J, Verneris MR, Ito M, Shizuru JA, Negrin RS. Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. Blood (2001) 97(10):2923-31. doi:10.1182/blood.V97.10.2923
33. Li XD, Xu B, Wu J, Ji M, Xu BH, Jiang JT, et al. Review of Chinese clinical trials on CIK cell treatment for malignancies. Clin Transl Oncol (2012) 14(2):102-8. doi:10.1007/s12094-012-0768-4
34. Cohen JE, Merims S, Frank S, Engelstein R, Peretz T, Lotem M. Adoptive cell therapy: past, present and future. Immunotherapy (2017) 9(2):183-96. doi:10.2217/imt-2016-0112
35. Bonanno G, Iudicone P, Mariotti A, Procoli A, Pandolfi A, Fioravanti D, et al. Thymoglobulin, interferon-gamma and interleukin-2 efficiently expand cytokine-induced killer (CIK) cells in clinical-grade cultures. J Transl Med (2010) 8:129. doi:10.1186/1479-5876-8-129
36. Rettinger E, Kuci S, Naumann I, Becker P, Kreyenberg H, Anzaghe M, et al. The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells. Cytotherapy (2012) 14(1):91-103. doi:10.3109/14653249.2011.613931
37. Mosinska P, Gabryelska A, Zasada M, Fichna J. Dual functional capability of dendritic cells - cytokine-induced killer cells in improving side effects of colorectal cancer therapy. Front Pharmacol (2017) 8:126. doi:10.3389/fphar.2017.00126
38. Laport GG, Sheehan K, Baker J, Armstrong R, Wong RM, Lowsky R, et al. Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant (2011) 17(11):1679-87. doi:10.1016/j.bbmt.2011.05.012
39. Linn YC, Niam M, Chu S, Choong A, Yong HX, Heng KK, et al. The anti-tumour activity of allogeneic cytokine-induced killer cells in patients who relapse after allogeneic transplant for haematological malignancies. Bone Marrow Transplant (2012) 47(7):957-66. doi:10.1038/bmt.2011.202
40. Introna M, Borleri G, Conti E, Franceschetti M, Barbui AM, Broady R, et al. Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. Haematologica (2007) 92(7):952-9. doi:10.3324/haematol.11132
41. Li Y, Schmidt-Wolf IG, Wu YF, Huang SL, Wei J, Fang J, et al. Optimized protocols for generation of cord blood-derived cytokine-induced killer/natural killer cells. Anticancer Res (2010) 30(9):3493-9.
42. Zhang Z, Zhao X, Zhang T, Wang L, Yang L, Huang L, et al. Phenotypic characterization and anti-tumor effects of cytokine-induced killer cells derived from cord blood. Cytotherapy (2015) 17(1):86-97. doi:10.1016/j.jcyt.2014.09.006
43. Zhang Z, Wang L, Luo Z, Zhao X, Huang J, Li H, et al. Efficacy and safety of cord blood-derived cytokine-induced killer cells in treatment of patients with malignancies. Cytotherapy (2015) 17(8):1130-8. doi:10.1016/j.jcyt.2015.04.002
44. Niu Q, Wang W, Li Y, Qin S, Wang Y, Wan G, et al. Cord blood-derived cytokine-induced killer cells biotherapy combined with second-line chemotherapy in the treatment of advanced solid malignancies. Int Immunopharmacol (2011) 11(4):449-56. doi:10.1016/j.intimp.2010.12.014
45. Thanendrarajan S, Kim Y, Schmidt-Wolf I. New adoptive immunotherapy strategies for solid tumours with CIK cells. Expert Opin Biol Ther (2012) 12(5):565-72. doi:10.1517/14712598.2012.668879
46. Jakel CE, Schmidt-Wolf IG. An update on new adoptive immunotherapy strategies for solid tumors with cytokine-induced killer cells. Expert Opin Biol Ther (2014) 14(7):905-16. doi:10.1517/14712598.2014.900537
47. Lin G, Wang J, Lao X, Li L, Li S, Zhang J, et al. Interleukin-6 inhibits regulatory T cells and improves the proliferation and cytotoxic activity of cytokine-induced killer cells. J Immunother (2012) 35(4):337-43. doi:10.1097/CJI.0b013e318255ada3
48. 6+ immunologic effector cells by receptor-mediated transfection with the interleukin-7 gene. Gene Ther (1998) 5(1):31-9. doi:10.1038/sj.gt.3300560
49. Zoll B, Lefterova P, Ebert O, Huhn D, Von Ruecker A, Schmidt-Wolf IG. Modulation of cell surface markers on NK-like T lymphocytes by using IL-2, IL-7 or IL-12 in vitro stimulation. Cytokine (2000) 12(9):1385-90. doi:10.1006/cyto.2000.0733
50. Yang Z, Zhang Q, Xu K, Shan J, Shen J, Liu L, et al. Combined therapy with cytokine-induced killer cells and oncolytic adenovirus expressing IL-12 induce enhanced antitumor activity in liver tumor model. PLoS One (2012) 7(9):e44802. doi:10.1371/journal.pone.0044802
51. 6+ cells and downregulating regulatory T cells as well as IL-35. J Immunother (2013) 36(9):462-7. doi:10.1097/CJI.0000000000000001
52. Wei C, Wang W, Pang W, Meng M, Jiang L, Xue S, et al. The CIK cells stimulated with combination of IL-2 and IL-15 provide an improved cytotoxic capacity against human lung adenocarcinoma. Tumour Biol (2014) 35(3):1997-2007. doi:10.1007/s13277-013-1265-2
53. Peng Z, Liang W, Li Z, Xu Y, Chen L. Interleukin-15-transferred cytokine-induced killer cells elevated anti-tumor activity in a gastric tumor-bearing nude mice model. Cell Biol Int (2016) 40(2):204-13. doi:10.1002/cbin.10553
54. Cappel C, Huenecke S, Suemmerer A, Erben S, Rettinger E, Pfirrmann V, et al. Cytotoxic potential of IL-15-activated cytokine-induced killer cells against human neuroblastoma cells. Pediatr Blood Cancer (2016) 63(12):2230-9. doi:10.1002/pbc.26147
55. Iudicone P, Fioravanti D, Cicchetti E, Zizzari IG, Pandolfi A, Scocchera R, et al. Interleukin-15 enhances cytokine induced killer (CIK) cytotoxic potential against epithelial cancer cell lines via an innate pathway. Hum Immunol (2016) 77(12):1239-47. doi:10.1016/j.humimm.2016.09.003
56. Cai C, Chen W, Miao D, Cheng L, Yang G, Zhang L, et al. Toll-like receptor 4 is required for the cytotoxicity of cytokine-induced killer cells. Acta Haematol (2014) 132(1):5-9. doi:10.1159/000355190
57. Wang W, Meng M, Zhang Y, Wei C, Xie Y, Jiang L, et al. Global transcriptome-wide analysis of CIK cells identify distinct roles of IL-2 and IL-15 in acquisition of cytotoxic capacity against tumor. BMC Med Genomics (2014) 7:49. doi:10.1186/1755-8794-7-49
58. Rajbhandary S, Zhao MF, Zhao N, Lu WY, Zhu HB, Xiao X, et al. Multiple cytotoxic factors involved in IL-21 enhanced antitumor function of CIK cells signaled through STAT-3 and STAT5b pathways. Asian Pac J Cancer Prev (2013) 14(10):5825-31. doi:10.7314/APJCP.2013.14.10.5825
59. Zhao N, Zhao MF, Rajbhandary S, Lu WY, Zhu HB, Ma L, et al. Effects and mechanism on anti-leukemic activity of cytokine-induced killer cells with an endogenous expression of interleukin-21. Zhonghua Yi Xue Za Zhi (2013) 93(4):293-9. doi:10.3760/cma.j.issn.0376-2491.2013.04.013
60. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature (1998) 392(6673):245-52. doi:10.1038/32588
61. Anguille S, Smits EL, Bryant C, Van Acker HH, Goossens H, Lion E, et al. Dendritic cells as pharmacological tools for cancer immunotherapy. Pharmacol Rev (2015) 67(4):731-53. doi:10.1124/pr.114.009456
62. Fernandez NC, Lozier A, Flament C, Ricciardi-Castagnoli P, Bellet D, Suter M, et al. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med (1999) 5(4):405-11. doi:10.1038/7403
63. Nicol A, Nieda M, Koezuka Y, Porcelli S, Suzuki K, Tadokoro K, et al. Human invariant valpha24+ natural killer T cells activated by alpha-galactosylceramide (KRN7000) have cytotoxic anti-tumour activity through mechanisms distinct from T cells and natural killer cells. Immunology (2000) 99(2):229-34. doi:10.1046/j.1365-2567.2000.00952.x
64. Cao J, Chen C, Wang Y, Chen X, Chen Z, Luo X. Influence of autologous dendritic cells on cytokine-induced killer cell proliferation, cell phenotype and antitumor activity in vitro. Oncol Lett (2016) 12(3):2033-7. doi:10.3892/ol.2016.4839
65. Pan Y, Tao Q, Wang H, Xiong S, Zhang R, Chen T, et al. Dendritic cells decreased the concomitant expanded Tregs and Tregs related IL-35 in cytokine-induced killer cells and increased their cytotoxicity against leukemia cells. PLoS One (2014) 9(4):e93591. doi:10.1371/journal.pone.0093591
66. Cui Y, Yang X, Zhu W, Li J, Wu X, Pang Y. Immune response, clinical outcome and safety of dendritic cell vaccine in combination with cytokine-induced killer cell therapy in cancer patients. Oncol Lett (2013) 6(2):537-41. doi:10.3892/ol.2013.1376
67. Shan CC, Shi LR, Ding MQ, Zhu YB, Li XD, Xu B, et al. Cytokine-induced killer cells co-cultured with dendritic cells loaded with the protein lysate produced by radiofrequency ablation induce a specific antitumor response. Oncol Lett (2015) 9(4):1549-56. doi:10.3892/ol.2015.2977
68. Wang YF, Kunda PE, Lin JW, Wang H, Chen XM, Liu QL, et al. Cytokine-induced killer cells co-cultured with complete tumor antigen-loaded dendritic cells, have enhanced selective cytotoxicity on carboplatin-resistant retinoblastoma cells. Oncol Rep (2013) 29(5):1841-50. doi:10.3892/or.2013.2315
69. Liu Y, Liu H, He P, Li J, Liu X, Chen L, et al. Dendritic cell-activated cytokine-induced killer cell-mediated immunotherapy is safe and effective for cancer patients >65 years old. Oncol Lett (2016) 12(6):5205-10. doi:10.3892/ol.2016.5337
70. Jung NC, Lee JH, Choi HJ, Hwang SU, Song JY, Seo HG, et al. Dendritic cell immunotherapy combined with cytokine-induced killer cells effectively suppresses established hepatocellular carcinomas in mice. Immunol Invest (2016) 45(6):553-65. doi:10.1080/08820139.2016.1183025
71. Lin M, Liang S, Jiang F, Xu J, Zhu W, Qian W, et al. 2003-2013, a valuable study: autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in stage IV breast cancer. Immunol Lett (2017) 183:37-43. doi:10.1016/j.imlet.2017.01.014
72. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity (2013) 39(1):1-10. doi:10.1016/j.immuni.2013.07.012
73. Preusser M, Lim M, Hafler DA, Reardon DA, Sampson JH. Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nat Rev Neurol (2015) 11(9):504-14. doi:10.1038/nrneurol.2015.139
74. Driessens G, Kline J, Gajewski TF. Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol Rev (2009) 229(1):126-44. doi:10.1111/j.1600-065X.2009.00771.x
75. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 12(4):252-64. doi:10.1038/nrc3239
76. Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E, et al. Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin Cancer Biol (2015) 35(Suppl):S185-98. doi:10.1016/j.semcancer.2015.03.004
77. Poh SL, Linn YC. Immune checkpoint inhibitors enhance cytotoxicity of cytokine-induced killer cells against human myeloid leukaemic blasts. Cancer Immunol Immunother (2016) 65(5):525-36. doi:10.1007/s00262-016-1815-8
78. Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy. Annu Rev Med (2013) 64:15-29. doi:10.1146/annurev-med-050311-201823
79. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer (2012) 12(4):278-87. doi:10.1038/nrc3236
80. Deng QI, Bai X, Lv HR, Xiao X, Zhao MF, Li YM. Anti-CD20 antibody induces the improvement of cytokine-induced killer cell activity via the STAT and MAPK/ERK signaling pathways. Exp Ther Med (2015) 9(4):1215-22. doi:10.3892/etm.2015.2264
81. Esser L, Weiher H, Schmidt-Wolf I. Increased efficacy of brentuximab vedotin (SGN-35) in combination with cytokine-induced killer cells in lymphoma. Int J Mol Sci (2016) 17(7):E1056. doi:10.3390/ijms17071056
82. Fan G, Wang Z, Hao M, Li J. Bispecific antibodies and their applications. J Hematol Oncol (2015) 8:130. doi:10.1186/s13045-015-0227-0
83. Tita-Nwa F, Moldenhauer G, Herbst M, Kleist C, Ho AD, Kornacker M. Cytokine-induced killer cells targeted by the novel bispecific antibody CD19xCD5 (HD37xT5.16) efficiently lyse B-lymphoma cells. Cancer Immunol Immunother (2007) 56(12):1911-20. doi:10.1007/s00262-007-0333-0
84. Chan JK, Hamilton CA, Cheung MK, Karimi M, Baker J, Gall JM, et al. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study. Clin Cancer Res (2006) 12(6):1859-67. doi:10.1158/1078-0432.CCR-05-2019
85. Zhang L, Hou Y, Zhang J, Hu J, Zhang K. Cytotoxicity of cytokine-induced killer cells targeted by a bispecific antibody to gastric cancer cells. Oncol Lett (2013) 5(6):1826-32. doi:10.3892/ol.2013.1281
86. Huang J, Li C, Wang Y, Lv H, Guo Y, Dai H, et al. Cytokine-induced killer (CIK) cells bound with anti-CD3/anti-CD133 bispecific antibodies target CD133(high) cancer stem cells in vitro and in vivo. Clin Immunol (2013) 149(1):156-68. doi:10.1016/j.clim.2013.07.006
87. Ma P, He Q, Li W, Li X, Han H, Jin M, et al. Anti-CD3 x EGFR bispecific antibody redirects cytokine-induced killer cells to glioblastoma in vitro and in vivo. Oncol Rep (2015) 34(5):2567-75. doi:10.3892/or.2015.4233
88. Oelsner S, Wagner J, Friede ME, Pfirrmann V, Genssler S, Rettinger E, et al. CAR-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-ALL and enhance survival. Int J Cancer (2016) 139(8):1799-809. doi:10.1002/ijc.30217
89. Marin V, Dander E, Biagi E, Introna M, Fazio G, Biondi A, et al. Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy. Exp Hematol (2006) 34(9):1219-29. doi:10.1016/j.exphem.2006.05.004
90. Marin V, Kakuda H, Dander E, Imai C, Campana D, Biondi A, et al. Enhancement of the anti-leukemic activity of cytokine induced killer cells with an anti-CD19 chimeric receptor delivering a 4-1BB-zeta activating signal. Exp Hematol (2007) 35(9):1388-97. doi:10.1016/j.exphem.2007.05.018
91. Hombach AA, Rappl G, Abken H. Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 "super-stimulation". Mol Ther (2013) 21(12):2268-77. doi:10.1038/mt.2013.192
92. Wu C, Jiang J, Shi L, Xu N. Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer. Anticancer Res (2008) 28(6B):3997-4002.
93. Niethammer AG, Wodrich H, Loeffler M, Lode HN, Emmerich K, Abdollahi A, et al. Multidrug resistance-1 (MDR-1): a new target for T cell-based immunotherapy. FASEB J (2005) 19(1):158-9. doi:10.1096/fj.04-2355fje
94. Liu P, Chen L, Huang X. The antitumor effects of CIK cells combined with docetaxel against drug-resistant lung adenocarcinoma cell line SPC-A1/DTX in vitro and in vivo. Cancer Biother Radiopharm (2009) 24(1):91-8. doi:10.1089/cbr.2008.0533
95. Zheng C, Yu G, Wang H, Tang A, Geng P, Zhang H, et al. Meta-analysis of chemotherapy and dendritic cells with cytokine-induced killer cells in the treatment of non-small-cell lung cancer. Int J Clin Exp Med (2015) 8(8):14527-37.
96. Han RX, Liu X, Pan P, Jia YJ, Yu JC. Effectiveness and safety of chemotherapy combined with dendritic cells co-cultured with cytokine-induced killer cells in the treatment of advanced non-small-cell lung cancer: a systematic review and meta-analysis. PLoS One (2014) 9(9):e108958. doi:10.1371/journal.pone.0108958
97. Mu Y, Zhou CH, Chen SF, Ding J, Zhang YX, Yang YP, et al. Effectiveness and safety of chemotherapy combined with cytokine-induced killer cell/dendritic cell-cytokine-induced killer cell therapy for treatment of gastric cancer in China: a systematic review and meta-analysis. Cytotherapy (2016) 18(9):1162-77. doi:10.1016/j.jcyt.2016.05.015
98. Wang ZX, Cao JX, Liu ZP, Cui YX, Li CY, Li D, et al. Combination of chemotherapy and immunotherapy for colon cancer in China: a meta-analysis. World J Gastroenterol (2014) 20(4):1095-106. doi:10.3748/wjg.v20.i4.1095
99. Liang C, Xu L, Song G, Liu Z. Emerging nanomedicine approaches fighting tumor metastasis: animal models, metastasis-targeted drug delivery, phototherapy, and immunotherapy. Chem Soc Rev (2016) 45(22):6250-69. doi:10.1039/c6cs00458j
100. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer (2005) 5(3):161-71. doi:10.1038/nrc1566
101. Phan JH, Moffitt RA, Stokes TH, Liu J, Young AN, Nie S, et al. Convergence of biomarkers, bioinformatics and nanotechnology for individualized cancer treatment. Trends Biotechnol (2009) 27(6):350-8. doi:10.1016/j.tibtech.2009.02.010
102. Cuenca AG, Jiang H, Hochwald SN, Delano M, Cance WG, Grobmyer SR. Emerging implications of nanotechnology on cancer diagnostics and therapeutics. Cancer (2006) 107(3):459-66. doi:10.1002/cncr.22035
103. Jin W, Cui D. Cancer nano-immunoengineering: the marriage of immunoengineering and nanotechnology for cancer. Nano Biomed Eng (2016) 8(2):105-6. doi:10.5101/nbe.v8i2.p105-107
104. Sanvicens N, Marco MP. Multifunctional nanoparticles - properties and prospects for their use in human medicine. Trends Biotechnol (2008) 26(8):425-33. doi:10.1016/j.tibtech.2008.04.005
105. Yezhelyev MV, Gao X, Xing Y, Al-Hajj A, Nie S, O'Regan RM. Emerging use of nanoparticles in diagnosis and treatment of breast cancer. Lancet Oncol (2006) 7(8):657-67. doi:10.1016/S1470-2045(06)70793-8
106. Swai H, Semete B, Kalombo L, Chelule P, Kisich K, Sievers B. Nanomedicine for respiratory diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2009) 1(3):255-63. doi:10.1002/wnan.33
107. Pison U, Welte T, Giersig M, Groneberg DA. Nanomedicine for respiratory diseases. Eur J Pharmacol (2006) 533(1-3):341-50. doi:10.1016/j.ejphar.2005.12.068
108. Irvine DJ, Hanson MC, Rakhra K, Tokatlian T. Synthetic nanoparticles for vaccines and immunotherapy. Chem Rev (2015) 115(19):11109-46. doi:10.1021/acs.chemrev.5b00109
109. Xu LG, Xiang J, Peng R, Liu Z. Recent advances in the development of nanomaterials for DC-based immunotherapy. Sci Bull (2016) 61(7):514-23. doi:10.1007/s11434-016-1038-6
110. Cambi A, Lidke DS, Arndt-Jovin DJ, Figdor CG, Jovin TM. Ligand-conjugated quantum dots monitor antigen uptake and processing by dendritic cells. Nano Lett (2007) 7(4):970-7. doi:10.1021/nl0700503
111. Lim YT, Noh YW, Han JH, Cai QY, Yoon KH, Chung BH. Biocompatible polymer-nanoparticle-based bimodal imaging contrast agents for the labeling and tracking of dendritic cells. Small (2008) 4(10):1640-5. doi:10.1002/smll.200800582
112. Reichardt W, Durr C, von Elverfeldt D, Juttner E, Gerlach UV, Yamada M, et al. Impact of mammalian target of rapamycin inhibition on lymphoid homing and tolerogenic function of nanoparticle-labeled dendritic cells following allogeneic hematopoietic cell transplantation. J Immunol (2008) 181(7):4770-9. doi:10.4049/jimmunol.181.7.4770
113. Long CM, van Laarhoven HWM, Bulte JWM, Levitsky HI. Magnetovaccination as a novel method to assess and quantify dendritic cell tumor antigen capture and delivery to lymph nodes. Cancer Res (2009) 69(7):3180-7. doi:10.1158/0008-5472.CAN-08-3691
114. Cruz LJ, Tacken PJ, Bonetto F, Buschow SI, Croes HJ, Wijers M, et al. Multimodal imaging of nanovaccine carriers targeted to human dendritic cells. Mol Pharm (2011) 8(2):520-31. doi:10.1021/mp100356k
115. Xiang J, Xu LG, Gong H, Zhu WW, Wang C, Xu J, et al. Antigen-loaded upconversion nanoparticles for dendritic cell stimulation, tracking, and vaccination in dendritic cell-based immunotherapy. ACS Nano (2015) 9(6):6401-11. doi:10.1021/acsnano.5b02014
116. Park YM, Lee SJ, Kim YS, Lee MH, Cha GS, Jung ID, et al. Nanoparticle-based vaccine delivery for cancer immunotherapy. Immune Netw (2013) 13(5):177-83. doi:10.4110/in.2013.13.5.177
117. Fontana F, Liu D, Hirvonen J, Santos HA. Delivery of therapeutics with nanoparticles: what's new in cancer immunotherapy? Wiley Interdiscip Rev Nanomed Nanobiotechnol (2017) 9(1):e1421. doi:10.1002/wnan.1421
118. Xiang SD, Wilson K, Day S, Fuchsberger M, Plebanski M. Methods of effective conjugation of antigens to nanoparticles as non-inflammatory vaccine carriers. Methods (2013) 60(3):232-41. doi:10.1016/j.ymeth.2013.03.036
119. Nembrini C, Stano A, Dane KY, Ballester M, van der Vlies AJ, Marsland BJ, et al. Nanoparticle conjugation of antigen enhances cytotoxic T-cell responses in pulmonary vaccination. Proc Natl Acad Sci U S A (2011) 108(44):E989-97. doi:10.1073/pnas.1104264108
120. Guo Y, Han W. Cytokine-induced killer (CIK) cells: from basic research to clinical translation. Chin J Cancer (2015) 34(3):99-107. doi:10.1186/s40880-015-0002-1
121. Lee JH, Lim YS, Yeon JE, Song TJ, Yu SJ, Gwak GY, et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology (2015) 148(7):1383-91.e6. doi:10.1053/j.gastro.2015.02.055
122. Weng DS, Zhou J, Zhou QM, Zhao M, Wang QJ, Huang LX, et al. Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas. J Immunother (2008) 31(1):63-71. doi:10.1097/CJI.0b013e31815a121b
123. Hui D, Qiang L, Jian W, Ti Z, Da-Lu K. A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma. Dig Liver Dis (2009) 41(1):36-41. doi:10.1016/j.dld.2008.04.007
124. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet (2000) 356(9232):802-7. doi:10.1016/S0140-6736(00)02654-4
125. Lee JH, Lee JH, Lim YS, Yeon JE, Song TJ, Yu SJ, et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology (2015) 148(7):1383-91. doi:10.1053/j.gastro.2015.02.055
126. Wang H, Liu A, Bo W, Feng X, Hu Y, Tian L, et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma patients after curative resection, a systemic review and meta-analysis. Dig Liver Dis (2016) 48(11):1275-82. doi:10.1016/j.dld.2016.07.010
127. Xie F, Zhang X, Li H, Zheng T, Xu F, Shen R, et al. Adoptive immunotherapy in postoperative hepatocellular carcinoma: a systemic review. PLoS One (2012) 7(8):e42879. doi:10.1371/journal.pone.0042879
128. Li X, Dai D, Song X, Liu J, Zhu L, Xu W. A meta-analysis of cytokine-induced killer cells therapy in combination with minimally invasive treatment for hepatocellular carcinoma. Clin Res Hepatol Gastroenterol (2014) 38(5):583-91. doi:10.1016/j.clinre.2014.04.010
129. Ma Y, Xu YC, Tang L, Zhang Z, Wang J, Wang HX. Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety. Exp Hematol Oncol (2012) 1(1):11. doi:10.1186/2162-3619-1-11
130. Li R, Wang C, Liu L, Du C, Cao S, Yu J, et al. Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study. Cancer Immunol Immunother (2012) 61(11):2125-33. doi:10.1007/s00262-012-1260-2
131. Chen Y, Lin WS, Zhu WF, Lin J, Zhou ZF, Huang CZ, et al. Tumor MICA status predicts the efficacy of immunotherapy with cytokine-induced killer cells for patients with gastric cancer. Immunol Res (2016) 64(1):251-9. doi:10.1007/s12026-015-8743-0
132. Chen Y, Lin J, Guo ZQ, Lin WS, Zhou ZF, Huang CZ, et al. MHC I-related chain a expression in gastric carcinoma and the efficacy of immunotherapy with cytokine-induced killer cells. Am J Cancer Res (2015) 5(10):3221-30.
133. Li X, Dai X, Shi L, Jiang Y, Chen X, Chen L, et al. Phase II/III study of radiofrequency ablation combined with cytokine-induced killer cells treating colorectal liver metastases. Cell Physiol Biochem (2016) 40(1-2):137-45. doi:10.1159/000452531
134. Wang M, Cao JX, Pan JH, Liu YS, Xu BL, Li D, et al. Adoptive immunotherapy of cytokine-induced killer cell therapy in the treatment of non-small cell lung cancer. PLoS One (2014) 9(11):e112662. doi:10.1371/journal.pone.0112662
135. Jin C, Li J, Wang Y, Chen X, Che Y, Liu X, et al. Impact of cellular immune function on prognosis of lung cancer patients after cytokine-induced killer cell therapy. Asian Pac J Cancer Prev (2014) 15(15):6009-14. doi:10.7314/APJCP.2014.15.15.6009
136. Zhao M, Li H, Li L, Zhang Y. Effects of a gemcitabine plus platinum regimen combined with a dendritic cell-cytokine induced killer immunotherapy on recurrence and survival rate of non-small cell lung cancer patients. Exp Ther Med (2014) 7(5):1403-7. doi:10.3892/etm.2014.1574
137. Zhang J, Zhu L, Du H, He X, Yin Y, Gu Y, et al. Autologous cytokine-induced killer cell therapy in lung cancer patients: a retrospective study. Biomed Pharmacother (2015) 70:248-52. doi:10.1016/j.biopha.2014.12.025
138. Zhang L, Yang X, Sun Z, Li J, Zhu H, Li J, et al. Dendritic cell vaccine and cytokine-induced killer cell therapy for the treatment of advanced non-small cell lung cancer. Oncol Lett (2016) 11(4):2605-10. doi:10.3892/ol.2016.4273
139. Jia H, Tian Y, Jiang CG, Han W. Evaluation of 29 indicators for the prognosis of advanced non-small cell lung cancer with cytokine-induced killer cell therapy combined with chemotherapy. Exp Ther Med (2016) 11(5):1601-10. doi:10.3892/etm.2016.3102
140. Zhao H, Wang Y, Yu J, Wei F, Cao S, Zhang X, et al. Autologous cytokine-induced killer cells improves overall survival of metastatic colorectal cancer patients: results from a phase II clinical trial. Clin Colorectal Cancer (2016) 15(3):228-35. doi:10.1016/j.clcc.2016.02.005
141. Lin T, Song C, Chuo DY, Zhang H, Zhao J. Clinical effects of autologous dendritic cells combined with cytokine-induced killer cells followed by chemotherapy in treating patients with advanced colorectal cancer: a prospective study. Tumour Biol (2016) 37(4):4367-72. doi:10.1007/s13277-015-3957-2
142. Kong DS, Nam DH, Kang SH, Lee JW, Chang JH, Kim JH, et al. Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in Korea. Oncotarget (2016) 8(4):7003-13. doi:10.18632/oncotarget.12273
143. Li H, Huang L, Liu LB, Wang XM, Zhang Z, Yue DL, et al. Selective effect of cytokine-induced killer cells on survival of patients with early-stage melanoma. Cancer Immunol Immunother (2017) 66(3):299-308. doi:10.1007/s00262-016-1939-x
144. Dutoit V, Migliorini D, Walker PR, Dietrich PY. Immunotherapy of brain tumors. Prog Tumor Res (2015) 42:11-21. doi:10.1159/000436986
145. Jiang J, Wu C, Lu B. Cytokine-induced killer cells promote antitumor immunity. J Transl Med (2013) 11:83. doi:10.1186/1479-5876-11-83
146. Minn AJ, Wherry EJ. Combination cancer therapies with immune checkpoint blockade: convergence on interferon signaling. Cell (2016) 165(2):272-5. doi:10.1016/j.cell.2016.03.031
147. Priceman SJ, Forman SJ, Brown CE. Smart CARs engineered for cancer immunotherapy. Curr Opin Oncol (2015) 27(6):466-74. doi:10.1097/CCO.0000000000000232